TrialJournal of neurology2016

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.

Scott D Newsome et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.